A
Asylia Therapeutics
Committed to transforming scientific advances into medicines for cancer & autoimmune diseases
About Asylia Therapeutics
Asylia Therapeutics, Inc. is a development-stage biotechnology company operating from Houston, Texas, focused on creating immunotherapies for cancer and autoimmune diseases. Founded in 2019, the company's scientific foundation stems from research conducted at The University of Texas MD Anderson Cancer Center by its co-founders: Robert Orlowski, M.D., Ph.D., Ronald A. DePinho, M.D., and Richard J. Jones, Ph.D. The company's creation was formalized in October 2020 through an exclusive worldwide license agreement with MD Anderson to develop these therapies. A significant milestone was achieved in May 2021 with the closing of a $14.5 million Series A financing round, led by Sporos Bioventures, to advance its assets toward human clinical trials. This funding also brought in Karthik Radhakrishnan as the founding CEO.
The core of Asylia's business is its drug development platform, which centers on modulating antigen presentation to the immune system. This approach aims to address a key challenge in immunotherapy: the inability of the immune system to recognize many types of cancer. The company's lead product candidate, ASY-77A, is an antibody that targets the extracellular form of Heat Shock Protein 70 (HSP70). This protein is crucial for delivering tumor antigens to dendritic cells, which then activate T-cells to attack and kill cancer cells. By enhancing this natural process, ASY-77A is designed to convert immunologically "cold" tumors, which are unresponsive to many treatments, into "hot" tumors that the immune system can effectively target. Pre-clinical models have shown ASY-77A to be effective against a variety of solid tumors, including breast and colon cancer, as well as blood-related cancers like multiple myeloma.
Asylia's business model is that of a privately held, venture-backed biotechnology firm in the pre-clinical trial stage. Its primary focus is on research and development to bring its novel antibody drugs through clinical trials and eventually to market. The company targets the oncology and autoimmune disease markets, with potential applications in conditions like lupus. Revenue generation is not yet a factor, as the company is concentrated on advancing its therapeutic pipeline. Its financial strategy has involved securing grants, including $3 million from the Cancer Prevention and Research Institute of Texas, and venture capital funding.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2021 | $15M | $58M | Sporos Bioventures | — |
| SPINOUT✓Other financing | Jan 2019 | $0 | — | University of Texas Health Science Center at Houston · MD Anderson Cancer Center | — |
Growth signals
Latest recorded traffic for Asylia Therapeutics is 640 monthly website visits, down 64.4% over the last three months. Asylia Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Asylia Therapeutics in the Houston ecosystem
The Asylia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Sporos Bioventures
Other known investors2 additional known investors
MD Anderson Cancer Center
University of Texas Health Science Center at Houston
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Asylia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Asylia Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










